Abstracts tagged "Infection"

Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting
Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
laurent chiche¹, sarah malaekah², alexandre belot³, Brigitte Bader-Meunier⁴, gregoire rey⁵, Noémie Jourde-Chiche Sr.⁶ and mireille eb⁵, ¹internal medicine, Hopital Europeen, Marseille, France, ²pediatry, CHU Lyon, Lyon, France, ³Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵cepidc, paris, France, ⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting
Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Orit Barrett¹, Ella Abramovich², Jacob Dreiher³, Victor Novack⁴ and Mahmoud Abu-Shakra⁵, ¹Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ²Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, ³Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, ⁴Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ⁵Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to identify the characteristics…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Ziv Paz¹, Mary Louise Fowler², Clara Zhu³, Sarah B. Lieber¹, Andrew Moore⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²School of Medicine, Boston University School of Medicine, Boston, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…
Abstract Number: 3238 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Adrian Richter¹, Anja Strangfeld², Prof. Dr. Matthias Schneider³, Thomas Klopsch⁴, Andreas Kapelle⁵, Jörg Kaufmann⁶, Angela Zink⁷ and Joachim Listing⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁴Rheumatologist in private practice, Neubrandenburg, Germany, ⁵Rheumatologist, Hoyerswerda, Germany, ⁶Medical practice specialising, Ludwigsfelde, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Tumor-necrosis-factor-α inhibition (TNFi) was assumed to be a relevant mechanism for the treatment of sepsis[1]. However, randomized controlled trials failed to show a survival…
Abstract Number: 1349 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of Septic Bursitis
Sarah B. Lieber¹, Clara Zhu², Mary Louise Fowler³, Andrew Moore⁴, Robert H. Shmerling⁵ and Ziv Paz¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medical School, Boston University School of Medicine, Boston, MA, ³School of Medicine, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Septic bursitis (SB) is a common condition that typically involves the olecranon and patellar bursae. It is unclear whether patients with SB treated surgically…
Abstract Number: 1357 • 2015 ACR/ARHP Annual Meeting
Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Yusuf Ziya Sener¹, Burak Yasin Aktas¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Ahmet Cagkan Inkaya³, Omer Karadag², Sule Apras Bilgen² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Infection Disease, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: CMV is a ubiquitous herpes virus associated with significant immunosuppression. Immunosuppressive treatments and ageing is well known risk factors for CMV reactivation. There are…
Abstract Number: 1450 • 2015 ACR/ARHP Annual Meeting
Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort
Daniel B. Horton^1,2,3, Brian L. Strom^1,3, Mary E. Putt³, Carlos D. Rose², David D. Sherry⁴ and Julia S. Sammons⁵, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Division of Pediatric Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, Infection Prevention and Control, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The incidence of Clostridium difficile infection (CDI) has increased among children, and CDI is associated with significant morbidity and mortality. Cases of C. difficile…
Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Bei-Hung Chang^1,2, Lien Quach¹, Mary Brophy³, Keri Hannagan⁴, Edward C. Keystone⁵, Ted R. Mikuls⁶ and James R. O'Dell⁷, ¹VA Boston Healthcare System, Boston, MA, ²Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ³VA Boston Heathcare System, Boston, MA, ⁴MAVERIC, VA Boston Heathcare System, Boston, MA, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
Abstract Number: 476 • 2014 ACR/ARHP Annual Meeting
Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Lucile Poiroux¹, Yannick Allanore², Andre Kahan³ and Jerome Avouac⁴, ¹Rhumatologie A, Cochin Hospital, Paris, France, ²Rheumatology, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, ³Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁴Cochin Hospital, Paris, France
Background/Purpose: TNF-a inhibitors have changed the prognosis of rheumatoid arthritis (RA). The number of molecules and the time of exposure have increased. However, few studies…
Abstract Number: 473 • 2014 ACR/ARHP Annual Meeting
Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids
Jacques Morel¹, Florence Tubach^2,3, Yannick Allanore⁴, Daniel Wendling⁵, Celine Cozic⁶, Emmanuelle Dernis Labous⁷, Eric Legangneux⁸, Thao Pham⁹, Sophie Odoit¹⁰, Isabelle Roitg¹¹, Isabelle Koné-Paut¹², Pierre Quartier¹³, Jean Sibilia¹⁴ and Severine Guillaume Czitrom¹⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ³INSERM, Universite Paris Diderot, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Rheumatology, CHD la Roche sur Yon, La Roche Sur Yon, France, ⁷Rhumatologie, Ch Du Mans, Le Mans, France, ⁸Rheumatology, Centre Hospitalier Public du Cotentin, 50100, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Dermatology, CHU de la Réunion, Saint Denis, France, ¹¹Hopital De Perpignan, Perpignan, France, ¹²Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁵Ch De Bicetre, Le Kremlin Bicetre Cedex, France
Background/Purpose To assess varicella zona virus (VZV) infection features under biological drugs. Methods A call for observations was sent from april 2013 to april 2014…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Charlotte Mabille¹, Adeline Ruyssen Witrand², Thomas Barnetche^3,4, Arnaud Constantin⁵ and Alain G. Cantagrel⁵, ¹Rheumatology Unit, hopital Purpan, Toulouse, France, ²Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ³rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁴Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁵Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].